疼痛管理治療薬の中南米市場2019–2027:医薬品クラス別(NSAIDS、麻酔薬、抗けいれん薬、抗片頭痛薬、抗うつ薬、オピオイド、非麻薬&鎮痛薬)、適応症別

【英語タイトル】LATAM Pain Management Drugs Market by Drug Class, (NSAIDS, Anesthetics, Anticonvulsant, Anti-Migraine Drugs, Antidepressant Drugs, Opioids, Non-Narcotics, and Analgesics), Indication (Arthritic Pain, Neuropathic Pain, Cancer Pain, Chronic Pain, Post-Operative Pain, Migraine, Fibromyalgia, Bone Fracture, Muscle Sprain/Strain, Acute Appendicitis, and Other Indications): Regional Opportunity Analysis and Industry Forecast, 2019–2027

Allied Market Researchが出版した調査資料(AMR20DC54)・商品コード:AMR20DC54
・発行会社(調査会社):Allied Market Research
・発行日:2020年10月
・ページ数:235
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:中南米
・産業分野:生命科学
◆販売価格オプション(消費税別)
Single UserUSD6,168 ⇒換算¥641,472見積依頼/購入/質問フォーム
5 UserUSD6,929 ⇒換算¥720,616見積依頼/購入/質問フォーム
Enterprise UserUSD9,663 ⇒換算¥1,004,952見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
本調査レポートでは、疼痛管理治療薬の中南米市場について調査・分析し、イントロダクション、エグゼクティブサマリー、市場動向、医薬品クラス別分析、疾患別分析、国別分析、企業情報などの項目を掲載しています。
【レポートの概要】

The LATAM pain management drugs market was valued at $2,683.82 million in 2019, and is projected to reach $3,383.20 million by 2027, registering a CAGR of 3.5% from 2020 to 2027.
Pain is a distressing sensory and emotional sensation, which is caused by tissue injury or disease. Moreover, different disorders may cause discomfort, such as multiple sclerosis, osteoarthritis, stomach ulcer, chronic arthritis, fibromyalgia, diabetic neuropathy, and cancer.

The length of pain ranges from acute pain for short term to chronic pain for long term. Acute pain is a sudden onset of pain while chronic pain is caused by aged bone & joint conditions, nerve damage, or injury. Pain management involves reducing or treating pain by using a given range of medications. There are several medicines available that provide pain relief through a variety of physiological mechanisms such as targeting nociceptors.

Rise in geriatric population is the major factor that drives growth of the LATAM pain management market, as aged people are more prone to suffer from joint pain and other chronic conditions. Moreover, surge in prevalence of chronic diseases, such as cancer, diabetic neuropathy, and osteoarthritis propels the market growth in Latin America. Furthermore, rise in number of surgical procedures and rise in healthcare expenditure are expected to fuel growth of the market. However, drug exploitation, patent expiration of prescription pain medication drugs, and availability of substitutes such as pain relief devices restrain the market growth in Latin America. The LATAM pain management drugs market is segmented on the basis of drug class, indication, and region. On the basis of drug class, the market is categorized into nonsteroidal anti-inflammatory drugs (NSAIDs), anesthetics, anticonvulsants, antimigraine agents, antidepressants, opioids, and nonnarcotic analgesics.
On the basis of indication, the market is divided into arthritic pain, neuropathic pain, cancer pain, chronic back pain, postoperative pain, migraine, fibromyalgia, bone fracture, muscle sprain, acute appendicitis, and others. By region, it is analyzed across Brazil, Argentina, Colombia, Peru, Chile, Ecuador, Panama, and rest of Latin America.

The key players operating in the LATAM pain management drugs market include Novartis AG, Eli Lilly & Company, Abbott Laboratories, Pfizer, Inc., Mylan NV., Merck & Co. Inc., Johnson & Johnson, and GlaxoSmithKline Plc. The other prominent players in the value chain include Allergen Inc., Bayer AG, Bristol-Myers Squibb, Valeant Pharmaceuticals International Inc., Boehringer Ingelheim, WEX Pharmaceuticals, and Zynerba Pharmaceuticals.

Drug class segment review
By drug class, the opioids segment was the largest contributor to the market in 2019, owing to high efficiency of opioids to relieve pain in major chronic conditions. The anesthetics segment is anticipated to possess highest growth rate during the forecast period.

Segment review
By indication, the neuropathic pain segment accounted for a majority of the market share in 2019, and is expected to exhibit a prominent growth rate during the forecast period. In addition, increase in presence of large patient population is the major factor that increases demand for drugs for the segment. Cancer pain and chronic back pain segments are expected to grow at the highest rate throughout the forecast period, owing to increase in number of surgeries in Latin America and rise in prevalence of chronic diseases that lead to back pain.

Brazil accounted for majority of the market share in 2019, and is expected to remain dominant throughout the forecast period. This was attributed to large number of aging population and favorable regulatory conditions. Rise in number of drug abuse cases and addictive nature of opioids has decreased use of prescriptions for opioids in the region, leading to decline in opioid consumption for pain management. On the other hand, Argentina is expected to experience highest growth rate during the forecast period, mainly attributable to presence of larger patient pool and increase in healthcare expenditure in the region.

KEY BENEFITS FOR STAKEHOLDERS
 The study provides an in-depth analysis of the LATAM pain management drug market along with the current trends and future estimations to elucidate the imminent investment pockets.
 A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
 The market forecast is studied from 2020 to 2027
 Comprehensive quantitative analysis of the industry from 2019 to 2027 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
 Extensive analysis of the key segments of the industry helps to understand the application and products of pain management used across the globe.
 Key market players and their strategies have been analysed to understand the competitive outlook of the market.

KEY MARKET SEGMENTS
By Drug Class
• NSAIDs
• Anesthetics
• Anticonvulsants
• Anti-migraine Agents
• Antidepressants
• Opioids
• Nonnarcotic Analgesics

By Indication
• Arthritic Pain
• Neuropathic Pain
• Cancer Pain
• Chronic Back Pain
• Postoperative Pain
• Migraine
• Fibromyalgia
• Bone fracture
• Muscle sprain
• Acute appendicitis
• Others

By Region
• LATAM
o Brazil
o Argentina
o Colombia
o Ecuador
o Panama
o Chile
o Peru
o Rest of Latin America

KEY MARKET PLAYERS
• Abbott Laboratories
• Eli Lilly & Company
• GlaxoSmithKline Plc.
• Johnson & Johnson
• Merck & Co. Inc.
• Mylan NV.
• Novartis AG
• Pfizer, Inc.
• Axon
• Sanofi
• GRÜNENTHAL

OTHER PROMINENT MARKET PLAYERS
• Allergen Inc.
• Bayer AG
• Bristol-Myers Squibb
• Boehringer Ingelheim
• Sorrento Therapeutics
• Valeant Pharmaceuticals International Inc.
• WEX Pharmaceuticals
• Zynerba Pharmaceuticals.

【レポートの目次】

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets
3.2.2.Top winning strategies

3.3.Top player positioning
3.4.Porter’s five force analysis for LATAM
3.5.Market dynamics

3.5.1.Drivers

3.5.1.1.Rise in incidences of chronic diseases
3.5.1.2.Favorable regulatory scenario
3.5.1.3.Increase in geriatric population

3.5.2.Restraints

3.5.2.1.Availability of alternative therapies
3.5.2.2.Drug exploitation
3.5.2.3.Patent expiration of prescription drugs

3.5.3.Opportunities

3.5.3.1.Advancements in drug development
3.5.3.2.Untapped markets in developing economies

3.6.COVID-19 impact analysis for LATAM Pain Management Drugs
3.7.Molecule information for LATAM

3.7.1.Brazil

3.7.1.1.NSAIDs
3.7.1.2.Opioids

3.7.2.Argentina

3.7.2.1.NSAIDs
3.7.2.2.Opioids

3.7.3.Colombia

3.7.3.1.NSAIDs
3.7.3.2.Opioids

3.7.4.Peru

3.7.4.1.NSAIDs
3.7.4.2.Opioids

3.7.5.Chile

3.7.5.1.NSAIDs
3.7.5.2.Opioids

3.7.6.Ecuador

3.7.6.1.NSAIDs
3.7.6.2.Opioids

3.7.7.Panama

3.7.7.1.NSAIDs
3.7.7.2.Opioids

CHAPTER 4:LATAM PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS

4.1.Overview

4.1.1.Market size and forecast

4.2.NSAIDs

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by country

4.3.Anesthetics

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by country

4.4.Anticonvulsants

4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by country

4.5.Antimigraine drug

4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by country

4.6.Antidepressant drugs

4.6.1.Key market trends, growth factors, and opportunities
4.6.2.Market size and forecast, by country

4.7.Opioids

4.7.1.Key market trends, growth factors, and opportunities
4.7.2.Market size and forecast, by country

4.8.Non-narcotic analgesics

4.8.1.Key market trends, growth factors, and opportunities
4.8.2.Market size and forecast, by country

CHAPTER 5:LATAM PAIN MANAGEMENT DRUGS MARKET, BY INDICATION

5.1.Overview

5.1.1.Market size and forecast

5.2.Arthritic pain

5.2.1.Market size and forecast, by country

5.3.Neuropathic pain

5.3.1.Market size and forecast, by country

5.4.Cancer pain

5.4.1.Market size and forecast, by country

5.5.Chronic back pain

5.5.1.Market size and forecast, by country

5.6.Post-operative pain

5.6.1.Market size and forecast, by country

5.7.Migraine

5.7.1.Market size and forecast, by country

5.8.Fibromyalgia

5.8.1.Market size and forecast, by country

5.9.Bone fracture

5.9.1.Market size and forecast, by country

5.10.Muscle sprain/strain

5.10.1.Market size and forecast, by country

5.11.Acute appendicitis

5.11.1.Market size and forecast, by country

5.12.Others

5.12.1.Market size and forecast, by country

CHAPTER 6:LATAM PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY

6.1.Overview
6.2.LATAM (Latin America)

6.2.1.Key market trends, growth factors, and opportunities
6.2.2.LATAM (Latin America)

6.2.2.1.Market size and forecast, by country
6.2.2.2.Market size and forecast, by drug class
6.2.2.3.Market size and forecast, by indication
6.2.2.4.Brazil

6.2.2.4.1.Market size and forecast, by drug class
6.2.2.4.2.Market size and forecast, by indication

6.2.2.5.Argentina

6.2.2.5.1.Market size and forecast, by drug class
6.2.2.5.2.Market size and forecast, by indication

6.2.2.6.Colombia

6.2.2.6.1.Market size and forecast, by drug class
6.2.2.6.2.Market size and forecast, by indication

6.2.2.7.Peru

6.2.2.7.1.Market size and forecast, by drug class
6.2.2.7.2.Market size and forecast, by indication

6.2.2.8.Chile

6.2.2.8.1.Market size and forecast, by drug class
6.2.2.8.2.Market size and forecast, by indication

6.2.2.9.Ecuador

6.2.2.9.1.Market size and forecast, by drug class
6.2.2.9.2.Market size and forecast, by indication

6.2.2.10.Panama

6.2.2.10.1.Market size and forecast, by drug class
6.2.2.10.2.Market size and forecast, by indication

6.2.2.11.Rest of Latin America

6.2.2.11.1.Market size and forecast, by drug class
6.2.2.11.2.Market size and forecast, by indication

CHAPTER 7:COMPANY PROFILES

7.1.ABBOTT LABORATORIES

7.1.1.Company overview
7.1.2.Company snapshot
7.1.3.Operating business segments
7.1.4.Product portfolio
7.1.5.Business performance

7.2.AXON PHARMA

7.2.1.Company overview
7.2.2.Company snapshot
7.2.3.Product portfolio

7.3.ELI LILY AND COMPANY

7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Operating business segments
7.3.4.Product portfolio
7.3.5.Business performance
7.3.6.Key strategic moves and developments

7.4.GRÜNENTHAL

7.4.1.Company overview
7.4.2.Company snapshot
7.4.3.Product portfolio
7.4.4.Business performance
7.4.5.Key strategic moves and developments

7.5.GLAXOSMITHKLINE PLC (GSK)

7.5.1.Company overview
7.5.2.Company snapshot
7.5.3.Operating business segments
7.5.4.Product portfolio
7.5.5.Business performance
7.5.6.Key strategic moves and developments

7.6.JOHNSON & JOHNSON

7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.6.5.Business performance

7.7.MERCK & CO., INC.

7.7.1.Company overview
7.7.2.Company snapshot
7.7.3.Operating business segments
7.7.4.Product portfolio
7.7.5.Business performance
7.7.6.Key strategic moves and developments

7.8.MYLAN N.V.

7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product portfolio
7.8.5.Business performance
7.8.6.Key strategic moves and developments

7.9.NOVARTIS INTERNATIONAL AG

7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product portfolio
7.9.5.Business performance
7.9.6.Key strategic moves and developments

7.10.PFIZER INC.

7.10.1.Company overview
7.10.2.Company snapshot
7.10.3.Operating business segments
7.10.4.Product portfolio
7.10.5.Business performance
7.10.6.Key strategic moves and developments

7.11.SANOFI

7.11.1.Company overview
7.11.2.Company snapshot
7.11.3.Operating business segments
7.11.4.Product portfolio
7.11.5.Business performance

LIST OF TABLES

TABLE 01.BRAZIL NSAIDS MARKET, BY MOLECULE, 2019, ($MILLION)
TABLE 02.BRAZIL OPIOIDS MARKET, BY MOLECULE, 2019, ($MILLION)
TABLE 03.ARGENTINA NSAIDS MARKET, BY MOLECULE, 2019, ($MILLION)
TABLE 04.ARGENTINA OPIOIDS MARKET, BY MOLECULE, 2019, ($MILLION)
TABLE 05.COLOMBIA NSAIDS MARKET, BY MOLECULE, 2019, ($MILLION)
TABLE 06.COLOMBIA OPIOIDS MARKET, BY MOLECULE, 2019, ($MILLION)
TABLE 07.PERU NSAIDS MARKET, BY MOLECULE, 2019, ($MILLION)
TABLE 08.PERU OPIOIDS MARKET, BY MOLECULE, 2019, ($MILLION)
TABLE 09.CHILE NSAIDS MARKET, BY MOLECULE, 2019, ($MILLION)
TABLE 10.CHILE OPIOIDS MARKET, BY MOLECULE, 2019, ($MILLION)
TABLE 11.ECUADOR NSAIDS MARKET, BY MOLECULE, 2019, ($MILLION)
TABLE 12.ECUADOR OPIOIDS MARKET, BY MOLECULE, 2019, ($MILLION)
TABLE 13.PANAMA NSAIDS MARKET, BY MOLECULE, 2019, ($MILLION)
TABLE 14.PANAMA OPIOIDS MARKET, BY MOLECULE, 2019, ($MILLION)
TABLE 15.LATAM PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 16.LATAM PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 (MILLION UNITS)
TABLE 17.LATAM PAIN MANAGEMENT DRUGS MARKET, BY NSAIDS, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 18.LATAM PAIN MANAGEMENT DRUGS MARKET, BY NSAIDS, BY COUNTRY, 2019–2027 (MILLION UNITS)
TABLE 19.LATAM PAIN MANAGEMENT DRUGS MARKET, BY ANESTHETICS, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 20.LATAM PAIN MANAGEMENT DRUGS MARKET, BY ANESTHETICS, BY COUNTRY, 2019–2027 (MILLION UNITS)
TABLE 21.LATAM PAIN MANAGEMENT DRUGS MARKET, BY ANTICONVULSANTS, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 22.LATAM PAIN MANAGEMENT DRUGS MARKET, BY ANTICONVULSANTS, BY COUNTRY, 2019–2027 (MILLION UNITS)
TABLE 23.LATAM PAIN MANAGEMENT DRUGS MARKET, BY ANTIMIGRAINE AGENTS, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 24.LATAM PAIN MANAGEMENT DRUGS MARKET, BY ANTIMIGRAINE AGENTS, BY COUNTRY, 2019–2027 (MILLION UNITS)
TABLE 25.LATAM PAIN MANAGEMENT DRUGS MARKET, BY ANTIDEPRESSANTS, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 26.LATAM PAIN MANAGEMENT DRUGS MARKET, BY ANTIDEPRESSANTS, BY COUNTRY, 2019–2027 (MILLION UNITS)S
TABLE 27.LATAM PAIN MANAGEMENT DRUGS MARKET, BY OPIOIDS, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 28.LATAM PAIN MANAGEMENT DRUGS MARKET, BY OPIOIDS, BY COUNTRY, 2019–2027 (MILLION UNITS)
TABLE 29.LATAM PAIN MANAGEMENT DRUGS MARKET, BY NON-NARCOTIC ANALGESICS, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 30.LATAM PAIN MANAGEMENT DRUGS MARKET, BY NON-NARCOTIC ANALGESIC, BY COUNTRY, 2019–2027 (MILLION UNITS)S
TABLE 31.LATAM PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 32.LATAM PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 (MILLION UNITS)S
TABLE 33.LATAM PAIN MANAGEMENT DRUGS MARKET, BY ARTHRITIC PAIN, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 34.LATAM PAIN MANAGEMENT DRUGS MARKET, BY ARTHRITIC PAIN, BY COUNTRY, 2019–2027 (MILLION UNITS)
TABLE 35.LATAM PAIN MANAGEMENT DRUGS MARKET, BY NEUROPATHIC PAIN, BY COUNTRY, 2019–2027 ($MILLION)S
TABLE 36.LATAM PAIN MANAGEMENT DRUGS MARKET, BY NEUROPATHIC PAIN, BY COUNTRY, 2019–2027 (MILLION UNITS)
TABLE 37.LATAM PAIN MANAGEMENT DRUGS MARKET, BY CANCER PAIN, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 38.LATAM PAIN MANAGEMENT DRUGS MARKET, BY CANCER PAIN, BY COUNTRY, 2019–2027 (MILLION UNITS)
TABLE 39.LATAM PAIN MANAGEMENT DRUGS MARKET, BY CHRONIC BACK PAIN, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 40.LATAM PAIN MANAGEMENT DRUGS MARKET, BY CHRONIC BACK PAIN, BY COUNTRY, 2019–2027 (MILLION UNITS)
TABLE 41.LATAM PAIN MANAGEMENT DRUGS MARKET, BY POST-OPERATIVE PAIN, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 42.LATAM PAIN MANAGEMENT DRUGS MARKET, BY POST-OPERATIVE PAIN, BY COUNTRY, 2019–2027 (MILLION UNITS)
TABLE 43.LATAM PAIN MANAGEMENT DRUGS MARKET, BY MIGRAINE, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 44.LATAM PAIN MANAGEMENT DRUGS MARKET, BY MIGRAINE, BY COUNTRY, 2019–2027 (MILLION UNITS)
TABLE 45.LATAM PAIN MANAGEMENT DRUGS MARKET, BY FIBROMYALGIA, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 46.LATAM PAIN MANAGEMENT DRUGS MARKET, BY FIBROMYALGIA, BY COUNTRY, 2019–2027 (MILLION UNITS)
TABLE 47.LATAM PAIN MANAGEMENT DRUGS MARKET, BY BONE FRACTURE, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 48.LATAM PAIN MANAGEMENT DRUGS MARKET, BY BONE FRACTURE, BY COUNTRY, 2019–2027 (MILLION UNITS)
TABLE 49.LATAM PAIN MANAGEMENT DRUGS MARKET, BY MUSCLE SPRAIN/STRAIN, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 50.LATAM PAIN MANAGEMENT DRUGS MARKET, BY SPRAIN/STRAIN, BY COUNTRY, 2019–2027 (MILLION UNITS)
TABLE 51.LATAM PAIN MANAGEMENT DRUGS MARKET, BY ACUTE APPENDICITIS, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 52.LATAM PAIN MANAGEMENT DRUGS MARKET, BY ACUTE APPENDICITIS, BY COUNTRY, 2019–2027 (MILLION UNITS)
TABLE 53.LATAM PAIN MANAGEMENT DRUGS MARKET, BY OTHERS, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 54.LATAM PAIN MANAGEMENT DRUGS MARKET, BY OTHERS, BY COUNTRY, 2019–2027 (MILLION UNITS)
TABLE 55.LATAM PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 56.LATAM PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY, 2019–2027 (MILLION UNITS)
TABLE 57.LATAM PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 58.LATAM PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 (MILLION UNITS)
TABLE 59.LATAM PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 60.LATAM PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 (MILLION UNITS)
TABLE 61.BRAZIL PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 62.BRAZIL PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 (MILLION UNITS)
TABLE 63.BRAZIL PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 64.BRAZIL PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 (MILLION UNITS)
TABLE 65.ARGENTINA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 66.ARGENTINA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 (MILLION UNITS)
TABLE 67.ARGENTINA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 68.ARGENTINA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 (MILLION UNITS)
TABLE 69.COLOMBIA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 70.COLOMBIA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 (MILLION UNITS)
TABLE 71.COLOMBIA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 72.COLOMBIA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 (MILLION UNITS)
TABLE 73.PERU PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 74.PERU PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 (MILLION UNITS)
TABLE 75.PERU PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 76.PERU PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 (MILLION UNITS)
TABLE 77.CHILE PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 78.CHILE PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 (MILLION UNITS)
TABLE 79.CHILE PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 80.CHILE PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 (MILLION UNITS)
TABLE 81.ECUADOR PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 82.ECUADOR PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 (MILLION UNITS)
TABLE 83.ECUADOR PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 84.ECUADOR PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 (MILLION UNITS)
TABLE 85.PANAMA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 86.PANAMA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 (MILLION UNITS)
TABLE 87.PANAMA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 88.PANAMA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 (MILLION UNITS)
TABLE 89.REST OF LATIN AMERICA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 90.REST OF LATIN AMERICA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 (MILLION UNITS)
TABLE 91.REST OF LATIN AMERICA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 92.REST OF LATIN AMERICA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 (MILLION UNITS)
TABLE 93.ABBOTT: COMPANY SNAPSHOT
TABLE 94.ABBOTT: OERATING SEGMENT
TABLE 95.ABBOTT: PRODUCT PORTFOLIO
TABLE 96.AXON PHARMA: COMPANY SNAPSHOT
TABLE 97.AXON PHARMA: PRODUCT PORTFOLIO
TABLE 98.ELI LILLY: COMPANY SNAPSHOT
TABLE 99.LILLY: OPERATING SEGMENTS
TABLE 100.ELI LILLY: PRODUCT PORTFOLIO
TABLE 101.ELI LILLY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 102.GRÜNENTHAL: COMPANY SNAPSHOT
TABLE 103.GRÜNENTHAL: PRODUCT PORTFOLIO
TABLE 104.GSK: COMPANY SNAPSHOT
TABLE 105.GSK: OPERATING SEGMENTS
TABLE 106.GSK: PRODUCT PORTFOLIO
TABLE 107.J&J: COMPANY SNAPSHOT
TABLE 108.J&J: OPERATING BUSINESS SEGMENTS
TABLE 109.J&J: PRODUCT PORTFOLIO
TABLE 110.MERCK & CO., INC.: COMPANY SNAPSHOT
TABLE 111.MERCK & CO., INC.: OPERATING SEGMENTS
TABLE 112.MERCK & CO., INC.: PRODUCT PORTFOLIO
TABLE 113.MERCK & CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 114.MYLAN: COMPANY SNAPSHOT
TABLE 115.MYLAN: OPERATING BUSINESS SEGMENTS
TABLE 116.MYLAN: PRODUCT PORTFOLIO
TABLE 117.NOVARTIS: COMPANY SNAPSHOT
TABLE 118.NOVARTIS: OPERATING SEGMENTS
TABLE 119.NOVARTIS: PRODUCT PORTFOLIO
TABLE 120.PFIZER: COMPANY SNAPSHOT
TABLE 121.PFIZER: OERATING SEGMENT
TABLE 122.PFIZER: PRODUCT PORTFOLIO
TABLE 123.SANOFI: COMPANY SNAPSHOSST
TABLE 124.SANOFI: OPERATING SEGMENTS
TABLE 125.SANOFI: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.LATAM PAIN MANAGEMENT DRUGS MARKET SEGMENTATION
FIGURE 02.TOP WINNING STRATEGIES, 2017–2020
FIGURE 03.TOP WINNING STRATEGIES: BY DEVELOPMENT , 2017–2020
FIGURE 04.TOP WINNING STRATEGIES: BY YEAR, 2017–2020
FIGURE 05.TOP PLAYER POSTIONING, 2019
FIGURE 06.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
FIGURE 08.MODERATE THREAT OF SUBSTITUTESS
FIGURE 09.MODEARTE THREAT OF NEW ENTRANTS
FIGURE 10.MODERATE COMPETITIVE OF RIVALRY
FIGURE 11.DRIVER, RESTRAINTS AND OPPORTUNITIES
FIGURE 12.LATAM PAIN MANAGEMENT DRUGS MARKET, 2020–2027 ($MILLION)
FIGURE 13.BRAZIL PAIN MANAGEMENT DRUGS MARKET, 2020–2027 ($MILLION)
FIGURE 14.ARGENTINA PAIN MANAGEMENT DRUGS MARKET, 2020–2027 ($MILLION)
FIGURE 15.COLOMBIA PAIN MANAGEMENT DRUGS MARKET, 2020–2027 ($MILLION)
FIGURE 16.PERU PAIN MANAGEMENT DRUGS MARKET, 2020–2027 ($MILLION)
FIGURE 17.CHILE PAIN MANAGEMENT DRUGS MARKET, 2020–2027 ($MILLION)
FIGURE 18.ECUADOR PAIN MANAGEMENT DRUGS MARKET, 2020–2027 ($MILLION)
FIGURE 19.PANAMA PAIN MANAGEMENT DRUGS MARKET, 2020–2027 ($MILLION)
FIGURE 20.REST OF LATIN AMERICA PAIN MANAGEMENT DRUGS MARKET, 2020–2027 ($MILLION)
FIGURE 21.ABBOTT: NET SALES, 2017–2019 ($MILLION)
FIGURE 22.ABBOTT: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 23.ABBOTT: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 24.ELI LILLY: NET SALES, 2017–2019 ($MILLION)
FIGURE 25.ELI LILLY: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 26.GRÜNENTHAL: NET SALES, 2017–2019 ($MILLION)
FIGURE 27.GSK: NET SALES, 2017–2019 ($MILLION)
FIGURE 28.GSK: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 29.GSK: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 30.J&J: NET SALES, 2017–2019 ($MILLION)
FIGURE 31.J&J: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 32.J&J: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 33.MERCK & CO., INC.: NET SALES, 2017–2019 ($MILLION)
FIGURE 34.MERCK & CO., INC.: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 35.MERCK & CO., INC.: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 36.MYLAN: NET SALES, 2017–2019 ($MILLION)
FIGURE 37.MYLAN: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 38.NOVARTIS: NET SALES, 2017–2019 ($MILLION)
FIGURE 39.NOVARTIS: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 40.NOVARTIS: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 41.PFIZER: NET SALES, 2017–2019 ($MILLION)
FIGURE 42.PFIZER: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 43.PFIZER: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 44.SANOFI: NET SALES, 2017–2019 ($MILLION)
FIGURE 45.SANOFI: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 46.SANOFI: REVENUE SHARE, BY REGION, 2019 (%)

★調査レポート[疼痛管理治療薬の中南米市場2019–2027:医薬品クラス別(NSAIDS、麻酔薬、抗けいれん薬、抗片頭痛薬、抗うつ薬、オピオイド、非麻薬&鎮痛薬)、適応症別] (コード:AMR20DC54)販売に関する免責事項を必ずご確認ください。
★調査レポート[疼痛管理治療薬の中南米市場2019–2027:医薬品クラス別(NSAIDS、麻酔薬、抗けいれん薬、抗片頭痛薬、抗うつ薬、オピオイド、非麻薬&鎮痛薬)、適応症別]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆